Carolyn Krasner is a Hematology physician affiliated with Dana-Farber Cancer Institute. OpenAlex indexes 143 publications with 3,965 citations (h-index 32); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit Street Yaw 9
Gillette Center For Women'S Cancer
Boston, MA 021142617
Telephone
617-724-3200Registry record last updated 11 Sept 2025.
Clinical trials
- Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
49.3%Phenothiazine23.9%Prochlorperazine Maleate100%Part D≥20 patientsGabapentinoids14.2%Gabapentin100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
24.6%Serotonin-3 Receptor Antagonist14.2%Ondansetron Hcl100%Part D≥12 patientsProton pump inhibitor10.4%Omeprazole100%Part D<11 patientsSensory organs
9%Corticosteroid9%Dexamethasone Sodium Phosphate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors
JNCI Journal of the National Cancer Institute
2023 - A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor–Positive Recurrent Endometrial Cancer
Journal of Clinical Oncology
2022 - Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma
Journal of Clinical Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”